Role of m6A methylation modification in bladder cancer

doi:10.16352/j.issn.1001-6325.2025.10.1372

Abstract

Abstract: N6 methyladenosine(m6A) methylation modification is a common form of mRNA modification, which is involved in the regulation of mRNA output, splicing, translation, localization and degradation, and plays an important role in the regulation of gene expression, body growth and development, and the development of tumors. The expression levels of many m6A methylation-related molecules in bladder cancer are altered to varying degrees, thus affecting the clinical treatment and prognosis of bladder cancer. The m6A methylation modification is closely related to the occurrence and development of bladder cancer, and a deeper understanding of the relevant regulatory mechanisms is beneficial to provide more reference for the clinical application of m6A methylation in bladder cancer.

Key words: bladder cancer, m6A methylation modification, methyltransferase, demethylase, methylation reader

CLC Number:

R737.14

LIU Yonghui, WU Yan, CHENG Bo. Role of m6A methylation modification in bladder cancer[J]. Basic & Clinical Medicine, 2025, 45(10): 1372-1376.

References

[1] Schwarzova L, Varchulova N Z, Danisovic L, et al. Molecular classification of urothelial bladder carcinoma[J]. Mol Biol Rep, 2023,50:7867-7877.
[2] Zhou Z, Zhang B, Deng Y, et al. FBW7/GSK3beta mediated degradation of IGF2BP2 inhibits IGF2BP2-SLC7A5 positive feedback loop and radioresistance in lung cancer[J]. J Exp Clin Cancer Res, 2024,43:34. doi:10.1186/s13046-024-02959-3.
[3] Sun L, Zhang Y, Yang B, et al. Lactylation of METTL16 promotes cuproptosis via m(6)A-modification on FDX1 mRNA in gastric cancer[J]. Nat Commun, 2023,14:6523.doi: 10.1038/s41467-023-42025-8.
[4] Oerum S, Meynier V, Catala M, et al. A comprehensive review of m6A/m6A/mRNA methyltransferase structures[J]. Nucleic Acids Res, 2021,49:7239-7255.
[5] Wang Y, Zhang L, Ren H, et al. Role of Hakai in m(6)A modification pathway in Drosophila[J]. Nat Commun, 2021,12:2159.doi: 10.1038/s41467-021-22424-5.
[6] Wen J, Lv R, Ma H, et al. Zc3h13 regulates nuclear RNA m(6)A methylation and mouse embryonic stem cell self-renewal[J]. Mol Cell, 2018,69:1028-1038.
[7] Xu C, Liu K, Tempel W, et al. Structures of human ALKBH5 demethylase reveal a unique binding mode for specific single-stranded N6-methyladenosine RNA demethylation[J]. J Biol Chem, 2014,289:17299-17311.
[8] Zhou C, She X, Gu C, et al. FTO fuels diabetes-induced vascular endothelial dysfunction associated with inflammation by erasing m6A methylation of TNIP1[J]. J Clin Invest, 2023,133.doi: 10.1172/JCI160517.
[9] Chen L, Gao Y, Xu S, et al. N6-methyladenosine reader YTHDF family in biological processes: Structures, roles, and mechanisms[J]. Front Immunol, 2023,14:1162607.doi: 10.3389/fimmu.2023.
[10] Zou Z, He C. The YTHDF proteins display distinct cellular functions on m(6)A-modified RNA[J]. Trends Biochem Sci, 2024,49:611-621.
[11] Muller S, Glass M, Singh A K, et al. IGF2BP1 promotes SRF-dependent transcription in cancer in a m6A- and miRNA-dependent manner[J]. Nucleic Acids Res, 2019,47:375-390.
[12] Zhang H, Wu D, Wang Y, et al. METTL3-mediated N6-methyladenosine exacerbates ferroptosis via m6A-IGF2BP2-dependent mitochondrial metabolic reprogram-ming in sepsis-induced acute lung injury[J]. Clin Transl Med, 2023,13:e1389.doi: 10.1002/ctm2.1389.
[13] Lin Z, Li J, Zhang J, et al. Metabolic reprogramming driven by IGF2BP3 promotes acquired resistance to EGFR inhibitors in non-small cell lung cancer[J]. Cancer Res, 2023,83:2187-2207.
[14] Zhang L, Li Y, Zhou L, et al. The m6A reader YTHDF2 promotes bladder cancer progression by suppressing RIG-I-mediated immune response[J]. Cancer Res, 2023,83:1834-1850.
[15] Tao L, Mu X, Chen H, et al. FTO modifies the m6A level of MALAT and promotes bladder cancer progression[J]. Clin Transl Med, 2021,11:e310.doi: 10.1002/ctm2.310.
[16] Song W, Yang K, Luo J, et al. Dysregulation of USP18/FTO/PYCR1 signaling network promotes bladder cancer development and progression[J]. Aging (Albany NY), 2021,13:3909-3925.
[17] Kong J, Lu S, Zhang L, et al. m6A methylation regulators as predictors for treatment of advanced urothelial carcinoma with anti-PDL1 agent[J]. Front Immunol, 2022,13:1014861.doi: 10.3389/fimmu.2022.1014861.
[18] Mao X, Chen X, Xu Z, et al. The identification of a N(6)-methyladenosin-modifed immune pattern to predict immunotherapy response and survival in urothelial carcinoma[J]. Aging (Albany NY), 2024,16:7774-7798.
[19] Zheng B, Wang J, Zhao G, et al. A new m6A methylation-related gene signature for prognostic value in patient with urothelial carcinoma of the bladder[J]. Biosci Rep, 2021,41:BSR20204456.doi: 10.1042/BSR20204456.
[20] Wang X, Yu J, Chen J, et al. Copy number variation analysis of m(6) A regulators identified METTL3 as a prognostic and immune-related biomarker in bladder cancer[J]. Cancer Med, 2021,10:7804-7815.
[21] Yang L, Ying J, Tao Q, et al. RNA N(6)-methyladenosine modifications in urological cancers: from mech-anism to application[J]. Nat Rev Urol, 2024,21:460-476.
[22] Wei Z, Chen Y, Zeng Z, et al. The novel m6A writer METTL5 as prognostic biomarker probably associating with the regulation of immune microenvironment in kidney cancer[J]. Heliyon, 2022,8:e12078.doi: 10.1016/j.heliyon.
[23] Wang B, Jiang J, Luo D, et al. Pan-cancer analysis reveals potential immunological and prognostic roles of METTL7A in human cancers[J]. Sci Rep, 2024,14:3476.doi: 10.1038/s41598-024-54255-x.
[24] Pierconti F, Rossi ED, Cenci T, et al. DNA methylation analysis in urinary samples: A useful method to predict the risk of neoplastic recurrence in patients with urothelial carcinoma of the bladder in the high-risk group[J]. Cancer Cytopathol, 2023,131:158-164.